Show simple item record

dc.contributor.authorSTORDAL, BRITTA KRISTINA
dc.date.accessioned2012-06-15T08:56:49Z
dc.date.available2012-06-15T08:56:49Z
dc.date.issued2009
dc.date.submitted2009en
dc.identifier.citationStordal, B. and Davey R, ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair., Cancer Chemotherapy and Pharmacology, 63, 4, 2009, 661 - 672en
dc.identifier.otherY
dc.identifier.urihttp://hdl.handle.net/2262/63712
dc.descriptionPUBLISHEDen
dc.description.abstractBackground: The H69CIS200 and H69OX400 cell lines are novel models of low- level platinum-drug resistance. Resistance was not associated with increased cellular glutathione or decreased accumulation of platinum, rather the resistant cell lines have a cell cycle alteration allowing them to rapidly proliferate post drug treatment. Results: A decrease in ERCC1 protein expression and an increase in RAD51B foci activity was observed in association with the platinum induced cell cycle arrest but these changes did not correlate with resistance or altered DNA repair capacity. The H69 cells and resistant cell lines have a p53 mutation and consequently decrease expression of p21 in response to platinum drug treatment, promoting progression of the cell cycle instead of increasing p21 to maintain the arrest. Conclusion: Decreased ERCC1 protein and increased RAD51B foci may in part be mediating the maintenance of the cell cycle arrest in the sensitive cells. Resistance in the H69CIS200 and H69OX400 cells may therefore involve the regulation of ERCC1 and RAD51B independent of their roles in DNA repair. The novel mechanism of platinum resistance in the H69CIS200 and H69OX400 cells demonstrates the multifactorial nature of platinum resistance which can occur independently of alterations in DNA repair capacity and changes in ERCC1.en
dc.format.extent661en
dc.format.extent672en
dc.language.isoenen
dc.publisherSpringer Verlagen
dc.relation.ispartofseriesCancer Chemotherapy and Pharmacology;63, 4
dc.rightsYen
dc.subjectCisplatinen
dc.subjectDNA Repairen
dc.subjectOxaliplatinen
dc.subjectERCC1en
dc.subjectRAD51Ben
dc.subjectSmall Cell Lung Canceren
dc.titleERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair.en
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/stordalb
dc.identifier.rssinternalid79799


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record